Charles R. Drew University of Medicine and Science (DREW) a minority institution (MSI/HBCU) located in South Central Los Angeles, is planning a partnership with the world renowned Jonsson Comprehensive Cancer Center (JCCC) at University of California Los Angeles (UCLA). The proposed partnership with the UCLA-JCCC provides a unique opportunity to begin to strengthen the DREW cancer research and training infrastructure. Conversely, UCLA and the investigators in the JCCC will have the important opportunity to address, in a focused manner, issues related to the unequal burden of cancer in minority populations. This partnership will focus on the areas of cancer research, training, education and outreach, and strengthen the DREW and UCLA research portfolios through programs that develop and enhance the capacity of investigators to perform high quality research with sensitivity toward reducing racial/ethnic disparities in health status. This application describes our plans to establish a comprehensive, seamless program of joint cancer research, training and career development by 1) integrating faculty, fellows, and students into various cancer training and career development programs;2) planning and initiating pilot projects;and 3) enhancing research capability of the DREW Tissue Repository. This program will recruit promising students, scientists, and clinicians at DREW and UCLA into the field of cancer research, education and treatment, and to retain these individuals within the combined DREW/UCLA cancer program. At the same time, we will increase the number of minority scientists in cancer research, treatment, education and training. Our training and career development programs will produce outstanding academic and culturally sensitive students, postdoctoral fellows, and faculty. These individuals will serve as our ambassadors toward understanding and therefore, reducing the burden of cancer in our underserved and socioeconomically disadvantaged populations. In view of the rapidly changing demographics of Los Angeles and the State of California, the DREW-UCLA Partnership is ideally situated and will have an opportunity to have a positive impact on the cancer incidence and survival in minority and underserved populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants--Cooperative Agreements (U56)
Project #
3U56CA101599-02S3
Application #
7913716
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J1))
Program Officer
Aguila, H Nelson
Project Start
2009-08-01
Project End
2010-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
2
Fiscal Year
2009
Total Cost
$25,000
Indirect Cost
Name
Charles R. Drew University of Medicine & Science
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Elshimali, Yahya I; Wu, Yong; Khaddour, Hussein et al. (2018) Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 1:
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:
Wu, Yong; Yu, Xiaoting; Yi, Xianghua et al. (2017) Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res 77:1383-1394
Bhat, Kruttika; Sarkissyan, Marianna; Wu, Yanyuan et al. (2017) GRO? overexpression drives cell migration and invasion in triple negative breast cancer cells. Oncol Rep 38:21-30
Chung, Seyung S; Adekoya, Debbie; Enenmoh, Ikechukwu et al. (2017) Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells. Anticancer Res 37:445-453
Wu, Yanyuan; Sarkissyan, Marianna; Vadgama, Jaydutt V (2016) Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med 5:
Wu, Yong; Dong, Yunzhou; Atefi, Mohammad et al. (2016) Lactate, a Neglected Factor for Diabetes and Cancer Interaction. Mediators Inflamm 2016:6456018
Chung, Seyung S; Vadgama, Jaydutt V (2015) Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NF?B signaling. Anticancer Res 35:39-46
Wu, Yong; Sarkissyan, Marianna; Mcghee, Eva et al. (2015) Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. Breast Cancer Res Treat 151:529-39
Wu, Yanyuan; Sarkissyan, Marianna; Vadgama, Jaydutt V (2015) Epigenetics in breast and prostate cancer. Methods Mol Biol 1238:425-66

Showing the most recent 10 out of 31 publications